{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+placebo&page=3",
    "query": {
      "intervention": "Vaccine placebo",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 984,
    "total_pages": 99,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+placebo&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+placebo&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T03:29:43.816Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06060457",
      "title": "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1900,
      "start_date": "2023-09-25",
      "completion_date": "2024-06-07",
      "has_results": true,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 34,
      "location_summary": "Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06060457"
    },
    {
      "nct_id": "NCT02296541",
      "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA Nat-B env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA CON-S env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA Mosaic env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-CMDR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Nat-B env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA CON-S env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Mosaic env",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MVA-CMDR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 105,
      "start_date": "2014-12",
      "completion_date": "2020-07-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296541"
    },
    {
      "nct_id": "NCT01984983",
      "title": "Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venezuelan Equine Encephalitis Virus Infection"
      ],
      "interventions": [
        {
          "name": "Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% saline placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ichor Medical Systems Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-12",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-08-26",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984983"
    },
    {
      "nct_id": "NCT00953524",
      "title": "A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Swine-origin A/H1N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution (placebo)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 849,
      "start_date": "2009-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 15,
      "location_summary": "Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00953524"
    },
    {
      "nct_id": "NCT01310413",
      "title": "Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza",
        "Influenza Vaccines"
      ],
      "interventions": [
        {
          "name": "Influenza A (H5N1) Virus monovalent vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 842,
      "start_date": "2011-03-07",
      "completion_date": "2014-01-26",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 11,
      "location_summary": "Paramount, California • Sacramento, California • Newton, Kansas + 8 more",
      "locations": [
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310413"
    },
    {
      "nct_id": "NCT07059182",
      "title": "Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE",
        "Prevention of Pneumococcal-induced Acute Otitis Media"
      ],
      "interventions": [
        {
          "name": "Inactivated whole-cell Streptococcus pneumoniae vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Serum Life Science Europe GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-11",
      "completion_date": "2025-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07059182"
    },
    {
      "nct_id": "NCT04886154",
      "title": "A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "MenABCWY-2Gen low dose vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenABCWY-2Gen high dose vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenB vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenACWY vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 1440,
      "start_date": "2021-06-14",
      "completion_date": "2024-02-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 12,
      "location_summary": "Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886154"
    },
    {
      "nct_id": "NCT04634513",
      "title": "Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Shigella Infection",
        "Enterotoxigenic Escherichia Coli Infection"
      ],
      "interventions": [
        {
          "name": "strain CVD 1208S-122",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 53,
      "start_date": "2022-09-29",
      "completion_date": "2024-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634513"
    },
    {
      "nct_id": "NCT04642638",
      "title": "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Infection",
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
        "COVID-19 Disease"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1307,
      "start_date": "2020-11-30",
      "completion_date": "2022-09-13",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 16,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04642638"
    },
    {
      "nct_id": "NCT04350138",
      "title": "Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonococcal Infection"
      ],
      "interventions": [
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2606,
      "start_date": "2020-12-29",
      "completion_date": "2026-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-05T03:29:43.816Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04350138"
    }
  ]
}